Werewolf Therapeutics Q1 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy HOWL?
Source: seekingalpha
- Earnings Surprise: Werewolf Therapeutics reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Position: As of March 31, 2026, the company had $46.5 million in cash and cash equivalents, down from $57.1 million as of December 31, 2025, highlighting concerns regarding the company's cash utilization in operations.
- Asset Purchase Agreement: Following the end of Q1, the company entered into an asset purchase agreement with Jazz and repaid all obligations under the loan and security agreement with K2, which will help improve the company's financial structure and reduce debt burden.
- Future Cash Guidance Update: The company plans to update its cash runway guidance in the near future, which will provide investors with a clearer financial outlook and may influence market perceptions of the company's future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOWL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOWL
Wall Street analysts forecast HOWL stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.620
Low
1.00
Averages
4.00
High
7.00
Current: 0.620
Low
1.00
Averages
4.00
High
7.00
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Werewolf Therapeutics Reports Q1 2026 Financial Results
- Improved Financial Performance: Werewolf Therapeutics reported a net loss of $13.53 million, or $0.28 per share in Q1 2026, which is an improvement from a net loss of $18.09 million, or $0.40 per share in the same period of 2025, indicating effective cost control measures.
- Reduced R&D Expenses: The company’s R&D expenses for the first quarter were $8.18 million, significantly down from $13.12 million in the previous year, reflecting progress in optimizing resource allocation and focusing on core projects, which may enhance future R&D efficiency.
- Cash Position: As of March 31, 2026, the company had $46.50 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation to support ongoing R&D and market expansion efforts, thereby strengthening its competitive position in the biopharmaceutical sector.
- Strategic Partnership Agreement: The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited, which acquired global development and commercialization rights for JZP898, not only broadening the company’s product pipeline but also potentially accelerating its market positioning and enhancing future revenue prospects.
See More
Werewolf Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Position: As of March 31, 2026, the company had $46.5 million in cash and cash equivalents, down from $57.1 million as of December 31, 2025, highlighting concerns regarding the company's cash utilization in operations.
- Asset Purchase Agreement: Following the end of Q1, the company entered into an asset purchase agreement with Jazz and repaid all obligations under the loan and security agreement with K2, which will help improve the company's financial structure and reduce debt burden.
- Future Cash Guidance Update: The company plans to update its cash runway guidance in the near future, which will provide investors with a clearer financial outlook and may influence market perceptions of the company's future growth prospects.
See More
Werewolf Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q4 GAAP EPS of -$0.20, beating expectations by $0.14, indicating an improvement in financial performance despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $57.1 million, down from $65.7 million as of September 30, 2025, reflecting challenges in operational cash management.
- Sufficient Funding: The company believes that its cash reserves as of December 31, 2025, will be adequate to cover operational expenses and capital requirements into Q4 2026, providing assurance for ongoing operations.
- Future Outlook: Despite current financial pressures, the company's optimism regarding future cash sufficiency suggests a degree of flexibility and resilience in its strategic planning.
See More
WEREWOLF THERAPEUTICS REPORTS Q4 NET LOSS OF USD 8.381 MILLION
Company Overview: Werewolf Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and other diseases.
Financial Performance: The company reported a net income of USD 8.381 million for the fourth quarter.
See More
Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs
- Workforce Reduction: Werewolf Therapeutics announced a 64% workforce cut to lower operating costs, with the reduction expected to be “substantially completed” by February 13, indicating an urgent response to financial pressures.
- One-Time Charge: The company anticipates incurring a one-time charge of $4.1 million in Q1, covering employee separation benefits including severance, which will negatively impact its short-term financial outlook.
- Executive Departures: CFO Timothy W. Trost and CMO Randi Isaacs will resign, receiving severance equal to nine months of their base salary, highlighting the risks associated with executive turnover during the restructuring process.
- Strategic Evaluation: The company is evaluating strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs, although there is no guarantee of successful financing or transactions, reflecting challenges in securing operational funding.
See More
Werewolf Therapeutics Board Approves Key Decision
- Board Decision: Werewolf Therapeutics announced on Friday in a regulatory filing that its board has approved a significant decision, although specific details remain undisclosed, this move could impact the company's future strategic direction.
- Regulatory Filing Submission: The announcement was made through a regulatory filing, indicating the company's commitment to transparency and compliance, which may enhance investor confidence.
- Market Reaction Anticipation: While specific details are currently unavailable, the market's reaction to the board's decision could influence Werewolf Therapeutics' stock performance, prompting investors to closely monitor subsequent information.
- Strategic Implications: The board's approval may signal a major shift in the company's R&D or business expansion efforts, reflecting its focus on future growth opportunities.
See More
Werewolf Therapeutics Reports Q1 2026 Financial Results
- Improved Financial Performance: Werewolf Therapeutics reported a net loss of $13.53 million, or $0.28 per share in Q1 2026, which is an improvement from a net loss of $18.09 million, or $0.40 per share in the same period of 2025, indicating effective cost control measures.
- Reduced R&D Expenses: The company’s R&D expenses for the first quarter were $8.18 million, significantly down from $13.12 million in the previous year, reflecting progress in optimizing resource allocation and focusing on core projects, which may enhance future R&D efficiency.
- Cash Position: As of March 31, 2026, the company had $46.50 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation to support ongoing R&D and market expansion efforts, thereby strengthening its competitive position in the biopharmaceutical sector.
- Strategic Partnership Agreement: The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited, which acquired global development and commercialization rights for JZP898, not only broadening the company’s product pipeline but also potentially accelerating its market positioning and enhancing future revenue prospects.
See More
Werewolf Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q1 GAAP EPS of -$0.28, beating expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Cash Position: As of March 31, 2026, the company had $46.5 million in cash and cash equivalents, down from $57.1 million as of December 31, 2025, highlighting concerns regarding the company's cash utilization in operations.
- Asset Purchase Agreement: Following the end of Q1, the company entered into an asset purchase agreement with Jazz and repaid all obligations under the loan and security agreement with K2, which will help improve the company's financial structure and reduce debt burden.
- Future Cash Guidance Update: The company plans to update its cash runway guidance in the near future, which will provide investors with a clearer financial outlook and may influence market perceptions of the company's future growth prospects.
See More
Werewolf Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Werewolf Therapeutics reported a Q4 GAAP EPS of -$0.20, beating expectations by $0.14, indicating an improvement in financial performance despite still being in a loss position.
- Cash Flow Status: As of December 31, 2025, the company's cash and cash equivalents stood at $57.1 million, down from $65.7 million as of September 30, 2025, reflecting challenges in operational cash management.
- Sufficient Funding: The company believes that its cash reserves as of December 31, 2025, will be adequate to cover operational expenses and capital requirements into Q4 2026, providing assurance for ongoing operations.
- Future Outlook: Despite current financial pressures, the company's optimism regarding future cash sufficiency suggests a degree of flexibility and resilience in its strategic planning.
See More
WEREWOLF THERAPEUTICS REPORTS Q4 NET LOSS OF USD 8.381 MILLION
Company Overview: Werewolf Therapeutics is a biotechnology company focused on developing innovative therapies for cancer and other diseases.
Financial Performance: The company reported a net income of USD 8.381 million for the fourth quarter.
See More
Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs
- Workforce Reduction: Werewolf Therapeutics announced a 64% workforce cut to lower operating costs, with the reduction expected to be “substantially completed” by February 13, indicating an urgent response to financial pressures.
- One-Time Charge: The company anticipates incurring a one-time charge of $4.1 million in Q1, covering employee separation benefits including severance, which will negatively impact its short-term financial outlook.
- Executive Departures: CFO Timothy W. Trost and CMO Randi Isaacs will resign, receiving severance equal to nine months of their base salary, highlighting the risks associated with executive turnover during the restructuring process.
- Strategic Evaluation: The company is evaluating strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs, although there is no guarantee of successful financing or transactions, reflecting challenges in securing operational funding.
See More
Werewolf Therapeutics Board Approves Key Decision
- Board Decision: Werewolf Therapeutics announced on Friday in a regulatory filing that its board has approved a significant decision, although specific details remain undisclosed, this move could impact the company's future strategic direction.
- Regulatory Filing Submission: The announcement was made through a regulatory filing, indicating the company's commitment to transparency and compliance, which may enhance investor confidence.
- Market Reaction Anticipation: While specific details are currently unavailable, the market's reaction to the board's decision could influence Werewolf Therapeutics' stock performance, prompting investors to closely monitor subsequent information.
- Strategic Implications: The board's approval may signal a major shift in the company's R&D or business expansion efforts, reflecting its focus on future growth opportunities.
See More
